E
Eduardo Candelario-Jalil
Researcher at University of Florida
Publications - 117
Citations - 6729
Eduardo Candelario-Jalil is an academic researcher from University of Florida. The author has contributed to research in topics: Ischemia & Neuroprotection. The author has an hindex of 43, co-authored 103 publications receiving 5486 citations. Previous affiliations of Eduardo Candelario-Jalil include University of New Mexico & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.
TL;DR: Regulation of the extracellular matrix by proteases and protease inhibitors is a fundamental biological process for normal growth, development and repair in the CNS.
Journal ArticleDOI
Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke.
TL;DR: This review discusses the current knowledge of how neuroinflammation contributes to BBB damage in ischemic stroke and provides an updated overview of the role of cytokines, chemokines, oxidative and nitrosative stress, adhesion molecules, matrix metalloproteinases, and vascular endothelial growth factor.
Journal ArticleDOI
Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration.
Carla R.A. Batista,Giovanni Freitas Gomes,Eduardo Candelario-Jalil,Bernd L. Fiebich,Antônio Carlos Pinheiro de Oliveira +4 more
TL;DR: The use of LPS in various models of neurodegeneration is reviewed as well as the neuroinflammatory mechanisms induced by this toxin that could underpin the pathological events linked to the Neurodegenerative process are discussed.
Journal ArticleDOI
Therapeutic efficacy of ozone in patients with diabetic foot.
Gregorio Martínez-Sánchez,Saied M. Al-Dalain,Silvia Menéndez,Lamberto Re,Attilia Giuliani,Eduardo Candelario-Jalil,Hector Alvarez,José Ignacio Fernández-Montequín,Olga Sonia León +8 more
TL;DR: Results show that medical ozone treatment could be an alternative therapy in the treatment of diabetes and its complications, resulting in fewer amputations than in control group and no side effects.
Journal ArticleDOI
Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.
TL;DR: There is still a substantial need for the development of therapeutic agents for neuroprotection in acute ischemic stroke to protect the brain from damage prior to and during recanalization, extend the therapeutic time window for intervention and further improve functional outcome.